Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics of EO- vs LO-PanNETs

Study in Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics Between Early- and Late-Onset Pancreatic Neuroendocrine Tumors: A Multicenter Retrospective Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07136701

Enrollment

600

Registered

2025-08-22

Start date

2025-08-31

Completion date

2027-07-31

Last updated

2026-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Neuroendocine Neoplasms (pNETs)

Keywords

EO-PanNET

Brief summary

The aim of this observational multicenter retrospective cohort study is to evaluate the differences in risk factors, prognosis, clinicopathological and metabolic characteristics between early-onset pancreatic neuroendocrine tumors (EO-PanNETs) and late-onset pancreatic neuroendocrine tumors (LO-PanNETs). The main questions it aims to answer are: Are there distinct clinical, pathological, and metabolic profiles in EO-PanNETs compared with LO-PanNETs? Do EO-PanNETs have different prognostic outcomes compared with LO-PanNETs? Researchers will compare EO-PanNET patients with LO-PanNET patients and with matched nonmalignant controls to assess differences in tumor characteristics and associated metabolic conditions. Participants will: Provide retrospective clinical, pathological, and metabolic data from hospital records. Have survival and recurrence outcomes assessed through follow-up data review.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* 18 years or older; histopathologically confirmed pancreatic neuroendocrine tumor by surgical resection or biopsy.

Exclusion criteria

* Pancreatic neuroendocrine carcinoma; incomplete pathological data; received antitumor treatment prior to presentation; with other malignanies or malignant history.

Design outcomes

Primary

Measure	Time frame
Overall Survival	From date of randomization until the date of death from any cause or the date of the last follow-up, whichever came first, assessed up to 12 years

Secondary

Measure	Time frame
Disease-specific survival	From date of diagnosis until death due to PanNETs, up to 12 years
Progression-free survival	From date of diagnosis until the date of disease recurrence or death from any cause, whichever came first, assessed up to 12 years.
Disease-free survival	From date of surgery until first documented recurrence, metastasis, or death from any cause, assessed up to 12 years.

Countries

China

Contacts

CONTACTHanxiang Zhan, MD. PhD.

zhanhanxiang@hotmail.com+86 18560085156

CONTACTChanghao Gao, MMed

gaochanghao44@gmail.com

Outcome results